AR024008A1 - Uso de microesferas biodegradables que liberan un agente anticancerigeno, para el tratamiento de glioblastoma, proceso para la preparacion de estasmicroesferas y suspension que contiene a las mismas - Google Patents

Uso de microesferas biodegradables que liberan un agente anticancerigeno, para el tratamiento de glioblastoma, proceso para la preparacion de estasmicroesferas y suspension que contiene a las mismas

Info

Publication number
AR024008A1
AR024008A1 ARP000102372A ARP000102372A AR024008A1 AR 024008 A1 AR024008 A1 AR 024008A1 AR P000102372 A ARP000102372 A AR P000102372A AR P000102372 A ARP000102372 A AR P000102372A AR 024008 A1 AR024008 A1 AR 024008A1
Authority
AR
Argentina
Prior art keywords
microspheres
biodegradable microspheres
over time
release
preparation
Prior art date
Application number
ARP000102372A
Other languages
English (en)
Original Assignee
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Lab Prod Ethiques filed Critical Ethypharm Lab Prod Ethiques
Publication of AR024008A1 publication Critical patent/AR024008A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se relaciona con el uso de microesferas biodegradables que liberan un agente anticancerígeno radiosensibilizante, para la fabricacion de unproducto medicinal que tiene la intension de ser usado en forma simultánea o separada en el tiempo,o diseminado con el tiempo, con una radioterapia, para eltratamiento de glioblastoma. El uso de las microesferas biodegradables de acuerdo con la presente logra un tiempo de supervivencia del paciente de por lo menos90 semanas, mientras que mantieneuna concentracion terapéuticamente efectiva con el tiempo en el espacio perenquimal. Las microesferas utilizadas conpreferencia contienen 5-fluorouracil, revestidas con poli(ácido d,1-láctico ácido co-glicolico). Las microesferas se implantan por inyeccion de intratejido,luego de la escision del tumor, en las paredes del lugar de operacion. La radioterapia focalizada en el volumen del tumor se dosifica a 60 G y duranteaproximadamente seis semanas. La presente además se relaciona con un procesopara la preparacion de microesferas biodegradables por extraccion de emulsion, asícomo también una suspension que contiene microesferas biodegradables que pueden obtenerse por medio de este proceso.
ARP000102372A 1999-05-17 2000-05-17 Uso de microesferas biodegradables que liberan un agente anticancerigeno, para el tratamiento de glioblastoma, proceso para la preparacion de estasmicroesferas y suspension que contiene a las mismas AR024008A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9906207A FR2793684B1 (fr) 1999-05-17 1999-05-17 Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant

Publications (1)

Publication Number Publication Date
AR024008A1 true AR024008A1 (es) 2002-09-04

Family

ID=9545636

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102372A AR024008A1 (es) 1999-05-17 2000-05-17 Uso de microesferas biodegradables que liberan un agente anticancerigeno, para el tratamiento de glioblastoma, proceso para la preparacion de estasmicroesferas y suspension que contiene a las mismas

Country Status (30)

Country Link
US (2) US6803052B2 (es)
EP (2) EP1228755A1 (es)
JP (1) JP5230045B2 (es)
KR (1) KR100649948B1 (es)
CN (1) CN1210020C (es)
AR (1) AR024008A1 (es)
AT (1) ATE228353T1 (es)
AU (1) AU775320B2 (es)
BG (1) BG64936B1 (es)
BR (1) BR0010648A (es)
CA (1) CA2388656C (es)
CZ (1) CZ20014137A3 (es)
DE (1) DE60000842T2 (es)
DK (1) DK1053746T3 (es)
EA (1) EA004943B1 (es)
ES (1) ES2185544T3 (es)
FR (1) FR2793684B1 (es)
HK (1) HK1047044B (es)
HU (1) HUP0201224A3 (es)
IL (2) IL146467A0 (es)
MX (1) MXPA01011919A (es)
NO (1) NO331686B1 (es)
NZ (1) NZ515515A (es)
PL (1) PL201614B1 (es)
PT (1) PT1053746E (es)
SI (1) SI1053746T1 (es)
SK (1) SK16342001A3 (es)
TW (1) TWI229608B (es)
WO (1) WO2000069413A1 (es)
ZA (1) ZA200109415B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342084T1 (de) 1999-08-05 2006-11-15 Map Medizin Technologie Gmbh Vorrichtung zur zufuhr eines atemgases und befeuchtungsvorrichtung
AUPR098300A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
JP2002154963A (ja) * 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
JP4510383B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 軟骨疾患修復治療用組成物
KR20040007596A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
EP1411861B1 (en) 2001-06-29 2012-04-04 Medgraft Microtech, Inc. Biodegradable injectable implants and related methods of manufacture and use
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US8986737B2 (en) 2002-09-05 2015-03-24 Wm. Marsh Rice University Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
NZ748073A (en) 2003-06-20 2020-06-26 ResMed Pty Ltd Breathable gas apparatus with humidifier
US20070026005A1 (en) * 2003-09-09 2007-02-01 Sung Young C Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
WO2005089398A2 (en) * 2004-03-18 2005-09-29 St. Luke's Hospital Method for the delivery of sustained release agents
US7833187B2 (en) 2004-04-16 2010-11-16 Nuvue Therapeutics, Inc. Systems and methods for improving image-guided tissue ablation
US8088413B2 (en) * 2004-04-16 2012-01-03 Nuvue Therapeutics, Inc. Methods for improved cryo-chemotherapy tissue ablation
CA2579533C (en) 2004-09-07 2013-05-21 Biocompatibles Uk Limited Drug delivery from embolic agents
US8702580B2 (en) * 2004-10-06 2014-04-22 Brainlab Ag Method and device for assisting in a tissue treatment
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
CN1299685C (zh) * 2005-01-26 2007-02-14 上海大学 氟尿嘧啶载药微球及其制备方法
CN100340297C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 抗癌体内植入剂
CN1923281B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含植物生物碱的抗癌缓释注射剂
CN100464785C (zh) * 2005-08-30 2009-03-04 孔庆忠 一种抗癌药物缓释注射剂及其应用
CN1923282B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含激素类药物的抗癌缓释注射剂
CN1923173B (zh) * 2006-02-24 2010-05-19 济南康泉医药科技有限公司 一种同载抗癌抗生素及其增效剂的抗癌药物缓释剂
WO2007105218A2 (en) * 2006-03-14 2007-09-20 Yeda Research And Development Co. Ltd. Composition and method for brain tumor therapy
CN100464736C (zh) * 2006-03-17 2009-03-04 山东蓝金生物工程有限公司 同载抗代谢药物及其增效剂的抗癌缓释注射剂
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
SG10201601349XA (en) 2011-12-13 2016-03-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
US10342769B2 (en) * 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
US20170128424A1 (en) * 2015-11-11 2017-05-11 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
AR112480A1 (es) 2017-08-24 2019-10-30 Novo Nordisk As Composiciones de glp-1 y sus usos
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
CA2269075A1 (en) * 1996-10-16 1998-04-23 Regeneron Pharmaceuticals, Inc. Method of enhancing the delivery of growth factors
WO1998043977A1 (fr) * 1997-03-31 1998-10-08 Toray Industries, Inc. Derives de quinolinomorphinane et leur usage medical
AU745324B2 (en) * 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin

Also Published As

Publication number Publication date
US7041241B2 (en) 2006-05-09
EA200101206A1 (ru) 2002-04-25
BG106106A (en) 2002-05-31
WO2000069413A1 (fr) 2000-11-23
JP2002544219A (ja) 2002-12-24
JP5230045B2 (ja) 2013-07-10
CN1210020C (zh) 2005-07-13
BR0010648A (pt) 2002-02-19
EP1053746A1 (fr) 2000-11-22
HUP0201224A2 (hu) 2002-11-28
ATE228353T1 (de) 2002-12-15
US20020051749A1 (en) 2002-05-02
AU4764100A (en) 2000-12-05
DE60000842D1 (de) 2003-01-09
BG64936B1 (bg) 2006-10-31
IL146467A0 (en) 2002-07-25
US20030175356A1 (en) 2003-09-18
ES2185544T3 (es) 2003-05-01
MXPA01011919A (es) 2002-05-06
HK1047044A1 (en) 2003-02-07
TWI229608B (en) 2005-03-21
FR2793684A1 (fr) 2000-11-24
NO20015501D0 (no) 2001-11-09
PL352372A1 (en) 2003-08-25
KR20020000178A (ko) 2002-01-04
EA004943B1 (ru) 2004-10-28
CN1356892A (zh) 2002-07-03
HUP0201224A3 (en) 2004-05-28
CA2388656C (fr) 2011-04-26
NZ515515A (en) 2004-02-27
DE60000842T2 (de) 2003-08-28
SK16342001A3 (sk) 2002-08-06
NO331686B1 (no) 2012-02-20
IL146467A (en) 2006-06-11
PT1053746E (pt) 2003-04-30
CA2388656A1 (fr) 2000-11-23
DK1053746T3 (da) 2003-03-31
EP1053746B1 (fr) 2002-11-27
SI1053746T1 (en) 2003-04-30
NO20015501L (no) 2002-01-09
PL201614B1 (pl) 2009-04-30
ZA200109415B (en) 2003-01-29
HK1047044B (zh) 2005-12-23
AU775320B2 (en) 2004-07-29
CZ20014137A3 (cs) 2002-06-12
FR2793684B1 (fr) 2001-08-10
US6803052B2 (en) 2004-10-12
KR100649948B1 (ko) 2006-11-24
EP1228755A1 (fr) 2002-08-07

Similar Documents

Publication Publication Date Title
AR024008A1 (es) Uso de microesferas biodegradables que liberan un agente anticancerigeno, para el tratamiento de glioblastoma, proceso para la preparacion de estasmicroesferas y suspension que contiene a las mismas
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
HK1053115A1 (en) Quinazoline derivatives for the treatment of tumours.
AR017752A1 (es) Composicion de matriz solida y porosa, metodo para su preparacion y metodo para la liberacion controlada de un agente terapeutico utilizando dichamatriz
ATE191506T1 (de) Gentherapeutische behandlung von gefässerkrankungen durch einen zellspezifischen, zellzyklusabhängigen wirkstoff
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
AR032912A1 (es) Formulacion farmaceutica
CA2416492A1 (en) Treatment of glycogen storage disease type ii
CO5540368A2 (es) Composicion de liberacion sostenida y proceso para producirla
AR037346A1 (es) Terapia de combinacion
ATE438385T1 (de) Pharmazeutische zusammensetzung
HRP20110365T1 (hr) Kombinacija azd2171 i pemetrekseda
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
AR006892A1 (es) Uso de formas del acido hialuronico (ha) para el tratamiento del cancer
BR9913782A (pt) Processo de preparação de uma formualação galênica que compreende fenofibrato como princìpio ativo, formulação galênica, medicamento e utilizações de um meio lìquido e de partìculas de fenofibrato
AU2599002A (en) Fusion cells and cytokine compositions for treatment of disease
IL147489A0 (en) Use of docetaxel for treating hepatocellular carcinoma
AR002027A1 (es) Formulaciones transdermicas y proceso para prepararlas.
ES2041243T3 (es) Aplicacion de por lo menos un principio activo inhibidor o destructor de por lo menos un ser vivo unicelular o virus.
PL357999A1 (en) Lhrh-antagonists, production and use thereof as medicament
Kontny et al. Anti-inflammatory activities of taurine chloramine: implication for immunoregulation and pathogenesis of rheumatoid arthritis
EE04966B1 (et) (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks
AR045258A1 (es) Un producto farmaceutico para inyeccion
ATE385798T1 (de) Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen
Shatskaya et al. Delivery of bleomycin A5 into cells using TiO 2 nanoparticles to enhance the degradation of intracellular DNA

Legal Events

Date Code Title Description
FB Suspension of granting procedure